ArticleThe oncologist2015
Potential for improvement in cancer management: reducing mortality in the European Union.
Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 44 citations in OpenAlex.
- Mortality of Three Major Gynecological Cancers in the European Region: An Age-Period-Cohort Analysis from 1992 to 2021 and Predictions in a 25‑Year Period.Annals of global health · 2025Article
- Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.BMC public health · 2024Article
- Age- and cause-specific contributions to increase in life expectancy at birth in Korea, 2000-2019: a descriptive study.BMC public health · 2024Article
- Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study.Journal of cancer research and clinical oncology · 2023Article
- Perspectives for Cancer Care and Research in Central and Eastern Europe.Oncology research and treatment · 2023Review
- A ten-year (2009-2018) database of cancer mortality rates in Italy.Scientific data · 2022Article
- Views of breast cancer survivors on work participation guidance by general practitioners: a qualitative study.BMC primary care · 2022Article
- Investigation on returning to work in liver cancer survivors in Taiwan: a 5-year follow-up study.BMC public health · 2021Article
- Risk factors for return to work in colorectal cancer survivors.Cancer medicine · 2021Article
- The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.The oncologist · 2020Article
- Standard Expected Years of Life Lost Due to Malignant Neoplasms in Poland, 2000-2014.International journal of environmental research and public health · 2019Article
- Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis.BMC cancer · 2019Article
- Clinical Impact of the Introduction of an Early Rehabilitation Protocol on Infectious Complications in Patients after Gastrointestinal Cancer Surgery.Progress in rehabilitation medicine · 2019Article
- Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe.The oncologist · 2019Article
- Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement.The oncologist · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overall age-standardized cancer mortality rates in the European Union (EU) have declined by approximately 20% through 2010 (17% in women, 22% in men) since the peak value reached in 1988. This corresponds to the avoidance of more than 250,000 cancer deaths in 2010 alone and approximately 2.2 million deaths over the 1989-2010 22-year period. A more than twofold difference remains between the highest cancer mortality rates (in Hungary and other central European countries) and the lowest (in selected Nordic countries and Switzerland). Part of this gap is due to tobacco, alcohol, and other lifestyle and environmental exposures, and another part is attributable to differences in cancer diagnosis, treatment, and management. There are also appreciable differences in 5-year cancer survival across the EU, with lower survival rates in central and eastern Europe. If overall cancer survival in EU countries with low rates could be raised to the median, approximately 50,000 additional cancer deaths would be avoided per year, and more than 100,000 would be avoided if overall survival in all countries were at least that of the 75% percentile--4% and 8%, respectively, of the approximately 1.3 million cancer deaths registered in the EU in 2010. There is, however, substantial uncertainty about any such estimate because differences in cancer survival are partly or largely attributable to earlier diagnosis, in variable proportion for each cancer site and probably to different degrees in different countries, even in the absence of changes in the date of death or avoidance of death. Consequently, these approximations are the best available and may be used cautiously to compare countries, health care approaches, and changes that occur over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.